PanDox: Targeted Doxorubicin in Pancreatic Tumours

Summary

This study will combine focused ultrasound to generate heat, and a heat-sensitive chemotherapy drug (ThermoDox®), delivered into the blood of participants with non-resectable pancreatic cancer. We will compare this to standard delivery of chemotherapy - the drug Doxorubicin given into the blood without the addition of ultrasound. We aim to determine whether the novel approach to delivering chemotherapy with heating the tumour by focused ultrasound can enhance the amount of drug delivered to pancreatic tumours. This will be measured by analysing a biopsy sample of treated tumour.

Timeline

Start

2021-06-16

Primary completion

2023-03-30

Completion

2023-03-30

Outcome

Outcome not reported

Stopped (Enrollment): “Lack of recruitment”

Publications

• Spiers L, Gray M, Lyon P, Sivakumar S, Bekkali N, Scott S, Collins L, Carlisle R, Wu F, Middleton M, Coussios C. Clinical trial protocol for PanDox: a phase I study of targeted chemotherapy delivery to non-resectable primary pancreatic tumours using thermosensitive liposomal doxorubicin (ThermoDox(R)) and focused ultrasound. BMC Cancer. 2023 Sep 23;23(1):896. doi: 10.1186/s12885-023-11228-z.

Drugs

Indications